What side effects are possible with Optalgin 500 mg?

Possible side effects and safety information

The regulatory safety profile for Metamizole (Optalgin) emphasizes a spectrum of possible effects, predominantly grouped into categories affecting the blood, immune system, skin, and cardiovascular function. This profile is defined by the potential for several rare but serious adverse reactions, which structure the official safety constraints for the medicine.

Documented Adverse Reactions and Frequencies

Adverse effects are classified based on their documented frequency in official sources. The most clinically significant risks are classified as Rare (occurring in 1 in 1,000 to 1 in 10,000 patients) or Very Rare (less than 1 in 10,000 patients).

Rare Adverse Reactions: Include specific hypersensitivity reactions (such as rash) and haematological conditions like Agranulocytosis and Leukopenia.
Very Rare Adverse Reactions: Include the severe and potentially life-threatening systemic reactions such as Anaphylactic Shock and the serious skin disorders Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Serious Adverse Reactions and System-Organ Classes

The official labeling notes that the serious haematological risks, such as agranulocytosis, are classified as not dose-related and may occur at any time during treatment. Other documented adverse effects involve the Vascular Disorders (Hypotension, Circulatory shock) and Renal and Urinary Disorders (Acute renal failure, Interstitial nephritis).

Population-Specific Safety Constraints

Specific official constraints apply to patient populations with pre-existing conditions, including known hypersensitivity to pyrazolone derivatives, impaired bone marrow function, acute hepatic porphyria, and certain immunological statuses such as bronchial asthma or chronic urticaria. Individuals with existing unstable circulation or specific organ impairments are also subject to particular safety considerations documented in the product labeling.

Therapeutic Uses of Optalgin 500 mg

What Optalgin 500 mg Treats: Main Uses and Benefits

The core therapeutic utility of Optalgin (Metamizole) is applied across domains where additional symptomatic support is needed, primarily addressing pain, fever, and spasm symptoms. It is commonly used in clinical settings marked by heightened patient distress and acute symptomatic discomfort across several key domains. It is indicated for the management of moderate to severe pain and fever.

The medication helps address symptom clusters that may become intense or disruptive. It is commonly used across conditions presenting with acute episodes of severe headache, toothache, pain following injury or surgery, and symptoms linked to organ-specific functional stress like renal or biliary colic.

Its application is relevant when supportive symptom management is appropriate, such as during phases when symptoms become more noticeable or for refractory fever that is unresponsive to other antipyretics. The medicine provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.

Quick Fact: Support for Symptoms of Severe Pain and Colic The medication is considered relevant in contexts marked by increased discomfort or tension, and helps address symptoms related to acute pain and those associated with smooth muscle spasms.

Regulatory References

European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Optalgin 500 mg (Metamizole) eligibility is strictly defined by regulatory documents, distinguishing between absolute prohibitions and conditional, restricted use.

Absolute Contraindications (Must Not Use)

Use of the medicine is contraindicated in specific populations. This includes infants below the age of 3 months or weighing less than 5 kg. It is also prohibited during the third trimester of pregnancy.

Individuals with a history of Metamizole hypersensitivity, analgesic-induced asthma, or known diseases affecting the hematopoietic system, such as impaired bone marrow function, are ineligible for use. Further prohibitions apply to patients with acute intermittent hepatic porphyria and glucose-6-phosphate-dehydrogenase (G6PD) deficiency.

Conditional and Restricted Use

The medicine is subject to limitations for certain groups. The 500 mg tablet strength is not recommended for children under 15 years old due to fixed dosage concerns. Use in the elderly and patients with impaired renal or hepatic function requires official caution; multiple high doses must be avoided, and a dose reduction may be necessary.

For breastfeeding women, official labels state that after a single administration, breastmilk must be discarded for a 48-hour period before breastfeeding can resume.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Metamizole (Optalgin 500 mg) is structured around two key constraints: pharmacokinetic and pharmacodynamic interactions. These constraints dictate specific restrictions, including substance prohibitions and required administration timing.

Interaction Classifications

The regulatory basis classifies certain co-administrations as Contraindicated and others as requiring intensive monitoring. Metamizole is documented as a moderate inducer of specific metabolic enzymes, which impacts the clearance of co-administered drugs.

Official Interaction Statements

Contraindicated Combination: Co-administration with Chlorpromazine is strictly prohibited due to the formally documented risk of severe hypothermia.
Pharmacokinetic Interaction (PK): Metamizole is an inducer of specific CYP enzymes (e.g., CYP2B6, CYP3A4). This enzyme induction can lead to a documented reduction in the plasma concentration of medicines metabolized by these pathways, including Ciclosporin, Tacrolimus, Bupropion, Methadone, and Efavirenz.
Timing Requirement: Metamizole can interfere with the antiplatelet effect of low-dose Acetylsalicylic Acid (ASA). Regulatory guidance mandates that Metamizole must be administered at least 1–2 hours after taking low-dose ASA to mitigate this pharmacodynamic interference.
Substance Interaction: Co-administration with alcohol results in a formally documented additive effect that enhances central nervous system effects.
Restriction: The use of Metamizole with Methotrexate is restricted due to the potential for haematotoxicity, requiring careful regulatory evaluation.

The regulatory documents define the product’s interaction structure by highlighting its role as an enzyme inducer and specifying mandatory time-based separations and outright prohibitions to manage clinically significant concentration changes and known additive risks.

Mechanism of Action

Optalgin 500 mg contains Metamizole, a prodrug that is rapidly metabolized into active compounds like 4-methylaminoantipyrine (MAA). The core mechanism involves a multi-modal action across the central nervous system (CNS) and smooth muscle tissues.

Central Inhibition of Key Mediators

The active metabolites inhibit the Cyclooxygenase-3 (COX-3) enzyme primarily in the CNS. This action reduces the synthesis of Prostaglandin E2 (PGE2) in the hypothalamus and spinal cord. Reduced PGE2 synthesis lowers the pain threshold and influences the hypothalamic temperature set point, which contributes to both analgesia and reduced body temperature.

Smooth Muscle Relaxation

The drug's metabolites interfere with intracellular signaling in smooth muscle cells by limiting the release of intracellular calcium (Ca^2+) stores. This Ca^2+ reduction promotes the relaxation of hypertonic smooth muscle, conferring the drug's spasmolytic action.

Neuromodulation

Metamizole also modulates the Endocannabinoid and Endogenous Opioidergic systems, enhancing the descending inhibitory control from the brain. The potentiation of these endogenous systems raises the pain threshold and modulates central pain processing.

Dosage and Administration Information

How to Use Optalgin 500 mg

The usage of Metamizole (the active ingredient in Optalgin 500 mg) is based on parameters that define the approved routes of administration, dose ranges, and specific requirements for proper intake. The overall principle is to administer the lowest effective dose for the shortest required duration.

Official Routes and Dose Ranges

The medication is administered via multiple routes, with instructions varying by form. The 500 mg strength primarily refers to the oral tablet or caplet dosage unit. Approved routes include oral (tablets, drops), intravenous (IV), intramuscular (IM), and rectal (suppositories).

Population	Single Dose Range (Oral)	Maximum Daily Dose (Oral)	Frequency (Oral)
Adults (≥ 15 yrs)	500 mg to 1,000 mg	4,000 mg	Up to 4 times daily

This regimen is based on established dosing protocols for Metamizole-containing products.

Administration and Scheduling Rules

The required interval between oral doses is typically 6 to 8 hours, ensuring the maximum daily limit is not exceeded. For children (≤ 14 years), dosing is calculated based on body weight, generally 8 mg to 16 mg per kilogram for a single dose. Lower doses are required for older adults and patients with impaired renal or hepatic function.

For the injectable solution, administration via the intravenous route must be performed very slowly and under proper monitoring. The effect is generally expected 30 to 60 minutes after oral intake.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Optalgin 500 mg

Research Evidence for Acute Pain and Spasms

Metamizole (Optalgin) was studied for acute pain that follows procedures like surgery or dental work, with the evidence evaluated in Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies research examined short-term symptom changes following a single dose. Researchers focused on outcomes related to physical discomfort, measuring the change in pain intensity and monitoring the time until participants sought additional relief. Similar comparative studies were conducted for acute pain associated with smooth muscle spasms, such as that linked to renal or biliary colic. In these trials, researchers focused on measuring outcomes describing episodic or acute changes in pain intensity.

Research Evidence for Refractory Fever

Metamizole was evaluated in Randomized Controlled Trials (RCTs) and reviews for conditions such as refractory fever. These studies research examined its use when fever appears to be unresponsive to other commonly used antipyretics. The research covered various populations, including pediatric groups (children) and adults in settings involving physiological strain. The outcomes monitored included measurements of change in body temperature, with studies report[ing] how symptoms evolved in the observed populations soon after administration.

Studies on Long-Term Outcomes and Limitations

Most available research focuses on short-term symptom changes that occur over hours or a few days. The follow-up durations were limited in the vast majority of efficacy trials. Long-term effects are not fully established, as research provides limited insight into outcomes related to daily functioning over weeks or months. Data for certain groups remain insufficient, particularly for older adults and patients with specific comorbid conditions. Evidence quality varies across studies, and sample sizes were modest in some specific trials, meaning the certainty of these findings remains low.

Frequently Asked Questions (FAQ)

Common questions about Optalgin 500 mg (FAQ)

Q: Is Optalgin 500 mg safe to use during pregnancy?

Regulatory documents state that the use of metamizole, the active ingredient in Optalgin 500 mg, is contraindicated during the third trimester of pregnancy. Official documents state that use during the first and second trimesters is generally discouraged, only permitting a single dose in selected clinical circumstances where no alternative treatments are available.

Q: Are there known interactions between Optalgin 500 mg and birth control pills?

Official information indicates that metamizole acts as an inducer of certain metabolic enzymes. This enzyme induction can lead to a documented reduction in the plasma concentration of other medicines. Since some oral contraceptives are metabolized by these pathways, a potential for reduced effectiveness is indicated, which is a factor considered for co-administration.

Q: Is the main purpose of Optalgin 500 mg to reduce swelling?

The medicine is primarily classified as a strong pain reliever (analgesic), a fever reducer (antipyretic), and a muscle spasm relaxer (spasmolytic). Official non-clinical research reports describe metamizole as having very little anti-inflammatory effect at therapeutic doses in humans, as it belongs to a different pharmacological class than traditional anti-inflammatory drugs.

Q: Is Optalgin 500 mg used only for pain?

Official therapeutic indications describe Optalgin 500 mg as addressing both strong pain and high fever that is unresponsive to other treatments. It is recognized for its combined action as an analgesic, antipyretic, and spasmolytic agent.

Q: Is Optalgin 500 mg described as being available over-the-counter or by prescription?

The regulatory status of metamizole, the active ingredient, is known to vary significantly across different regions. In some countries, it is strictly classified as a prescription-only medicine, while in others, it is available over-the-counter with certain restrictions.

Q: Does Optalgin 500 mg interact with common flu or cold medicines?

Official documents specify that metamizole can interfere with the effect of other medicines by reducing their plasma concentrations. Users should exercise caution with any combination product, as many flu and cold medicines contain ingredients metabolized by the same enzyme pathways.

Q: What is the difference between Optalgin 500 mg and standard ibuprofen?

Ibuprofen is classified as a traditional Non-Steroidal Anti-Inflammatory Drug (NSAID). Optalgin (Metamizole) is classified as an atypical non-opioid analgesic and is recognized for its potent spasmolytic (muscle-relaxing) action and primary central nervous system effect, which distinguishes it from traditional NSAIDs.

Q: Why is Optalgin 500 mg not available in all countries?

Regulatory bodies in some countries have previously withdrawn or banned the use of metamizole in humans due to concerns related to a rare but serious side effect. The drug remains available in many other countries, reflecting differing regulatory evaluations of its risk-benefit profile.

Q: Is Optalgin 500 mg known to cause drowsiness?

The official safety profile lists somnolence (drowsiness) as a reported adverse event.

Q: What are the most common reported side effects of Optalgin 500 mg?

Common adverse events listed in regulatory documents include nausea, vomiting, headache, weakness, fever, abdominal pain, somnolence (drowsiness), and rash. The safety profile also highlights the potential for rare, serious haematological risks like agranulocytosis.

Q: Is it possible to become dependent on Optalgin 500 mg?

Optalgin 500 mg is classified in regulatory documents as a non-opioid analgesic. This classification is used to distinguish it from opioid pain relievers, which are the class of drugs associated with a documented risk of dependency and abuse potential.

Q: What should I do if I miss a scheduled time for Optalgin 500 mg?

Official guidance emphasizes that the medication should be taken at a regular interval (typically 6 to 8 hours) and that the maximum daily limit must not be exceeded. This regulatory emphasis on time intervals is intended to prevent the maximum daily limit from being exceeded.

Q: Is Optalgin 500 mg related to acetaminophen (paracetamol)?

Optalgin (Metamizole) is chemically classified as a pyrazolone derivative. This means it belongs to a different chemical group than acetaminophen (paracetamol) and traditional NSAIDs, which accounts for its unique mechanism of action.

Q: Does Optalgin 500 mg contain caffeine?

According to the official composition provided in regulatory documents, the Optalgin 500 mg formulation is a monotherapy containing the active substance Metamizole (or Metamizole sodium). The official composition does not list caffeine as an active ingredient.

Q: Are there official warnings about driving or operating machinery while using Optalgin 500 mg?

Official labeling typically states that, at the recommended dosage, no effect on driving ability is known. However, because adverse effects like drowsiness or dizziness are possible, official information indicates that caution should be exercised when performing tasks that require concentration.

Q: What is the evidence regarding the use of Optalgin 500 mg for toothache?

Research reviews from authoritative sources describe metamizole as being studied for acute pain, including pain that follows dental work. The evidence examined how effective it was in providing short-term relief from pain intensity in this context.

Q: Does Optalgin 500 mg cause changes in mood?

The official safety profile (SmPC) classifies adverse effects by system. While psychiatric disorders are a standard classification, metamizole labeling generally does not list common mood changes as a frequently reported adverse event.

Q: Why might Optalgin 500 mg be prescribed instead of a different pain reliever?

Metamizole is officially recognized for its triple action as an analgesic, antipyretic, and strong spasmolytic (muscle-relaxing) agent. Its selection is often associated with therapeutic scenarios where pain is directly linked to the involuntary contraction of smooth muscles, such as in cases of renal or biliary colic.

Q: Are there any known long-term effects associated with Optalgin 500 mg use?

Official research summaries note that the follow-up durations in most efficacy trials were limited, meaning that long-term effects are not fully established. The serious haematological risks like agranulocytosis are stated to be not dose-related and may occur at any point during treatment.

Q: What does the research say about Optalgin 500 mg for post-operative pain?

Official systematic reviews and randomized controlled trials research examined metamizole for relief of acute pain that follows procedures like surgery. The findings were related to its effectiveness in providing short-term changes in pain intensity shortly after administration.

Q: Can Optalgin 500 mg be crushed or split?

The ability to split or crush a tablet is determined by its specific pharmaceutical formulation (e.g., whether it is scored or coated). Official documents typically contain instructions for splitting or crushing only if the tablet is scored or specifically designed for this purpose. Without such instructions, the recommended use is as a whole tablet.

Q: Does Optalgin 500 mg have anti-inflammatory properties?

Official non-clinical research documents state that metamizole is an atypical analgesic that lacks significant anti-inflammatory properties at human therapeutic doses. Its primary actions are focused on pain relief, fever reduction, and muscle spasm relaxation.

How should Optalgin 500 mg be stored and disposed of?

How to Store and Dispose of Optalgin 500 mg?

Regulatory documents outline specific requirements for the storage and disposal of Optalgin (metamizole) to ensure product stability and safety.

Storage Conditions

Storage Requirement	Official Constraint
Temperature	Store not above 25 C.
Protection	Protect from light by storing in the original package.
Prohibited Environment	Do not store in the freezer.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Any unused medicinal product or waste material must be discarded. Disposal should be carried out according to local regulations for pharmaceutical waste. This ensures proper handling and environmental safety for the unused portion of the medicine.

Property	Description
Active ingredient	Metamizole (or Dipyrone)
Form	Tablet, Caplet, Solution for injection
Pharmacological class	Non-opioid analgesic, antipyretic, spasmolytic
Common use	Relief of pain, reduction of fever
Origin	Synthetic (Pyrazolone derivative)

Category	Official Regulatory Statements
Documented overdose presentations	Initial manifestations documented include gastrointestinal symptoms (nausea, vomiting, abdominal pain) and central nervous system disturbances such as restlessness, somnolence, and convulsions. Physiological findings may include increased respiration, salivation, and electrolyte imbalances.
Physiological systems affected	Official labeling identifies effects on the Central Nervous, Cardiovascular, and Renal Systems. Severe outcomes documented include circulatory collapse (shock) due to profound hypotension, acute kidney failure, and respiratory paralysis.
Emergency-response statements	Treatment is entirely symptomatic and supportive, as no specific antidote is known. Procedures include gastrointestinal decontamination, monitoring of vital signs, and advanced supportive care, such as hemodialysis for severe acidosis or renal compromise.
When immediate medical help is required	Regulatory guidance mandates to seek immediate medical attention upon the suspicion of an overdose. Urgent medical assistance is also required if severe adverse reaction symptoms, such as fever or sore throat potentially indicative of agranulocytosis, appear.

Optalgin 500 mg